GlobalData on MSN2d
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients
The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
Precision BioSciences presents preclinical data from PBGENE-DMD program
Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...
Yahoo Finance2d
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients
Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy (DMD). Results from the company’s ...
Pharmabiz2d
Roche to present latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association 2025 conference
Roche to present latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association 2025 conference: Basel Tuesday, March 18, 2025, 11:00 Hrs [IST] ...
Business Wire24d
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Presentation Details: Title: ARCUS-Mediated Excision of Exons 45-55 Leads to Functional Del45-55 Dystrophin and Restoration of Skeletal Muscle-Function for the Treatment of DMD Date and Time ...
Nasdaq3d
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission
"The amount of expression of near-full length dystrophin induced by DYNE-251 has ... and has preclinical programs targeting other exons, including 53, 45 and 44. About Duchenne Muscular Dystrophy ...
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Detailed price information for Entrada Therapeutics Inc (TRDA-Q) from The Globe and Mail including charting and trades.